drugset / Trial / NCT02245256
Efficacy of Low-dose Dexmedetomidine to Prevent Delirium in Liver Transplant Patients
Phase 4
Completed
217 enrolled
Seoul National University Hospital
Hospira, now a wholly owned subsidiary of Pfizer · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
To test the effect of low-dose dexmedetomidine for lowering the incidence of postoperative delirium in liver transplant patients in the ICU. Single center prospective randomized placebo controlled clinical trial 0.1mcg/kg/hr of dexmedetomidine or equivalent amount of saline infusion started after induction of anesthesia for liver transplantation and continued until 48 hours after surgery. Outcomes will be assessed up to 1 week or transfer to ward, whichever comes first.
Timeline
- Start
- 2014-09-01
- Primary completion
- 2018-01-01
- Completion
- 2018-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexmedetomidine | Other / unclassified | 0.1 ug/kg | — |
Indications
No indication recorded.